April 3, 2025 10:27 AM EDT

MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund

Jaimy Lee

Deputy Editor

MoonLake Immunotherapeutics gets financing worth up to $500M: The company will get $75 million upfront from Hercules Capital. MoonLake, which went …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Merck KGaA closes in on SpringWorks deal at $3.5B price point

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Moon­Lake dis­clos­es up to $500M in fi­nanc­ing; OSR’s deal with in­no­va­tion fund

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Merck KGaA closes in on SpringWorks deal at $3.5B price point

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence